IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills Curriculum to Support Evidence-Based Treatment Decisions

Effective management is crucial for improving the care of patients with moderate to severe atopic dermatitis (AD). In this program, HCPs will learn about the pathophysiologic contributions of IL-13 in AD and how to assess patient candidacy for therapies targeting IL-13 through interactive case challenges, expert commentaries, podcasts, and downloadable slides.

Share

Program Content

Activities

Atopic Dermatitis Treatment
Targeting IL-13: A New Era in Atopic Dermatitis Treatment 
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

Targeting IL 13 in AD
Pathophysiologic Rationale for Targeting IL-13 in Atopic Dermatitis 
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 23, 2025

Expires: January 22, 2026

Activities

IL-13 in Moderate to Severe Atopic Dermatitis
Advanced IL-13 Targeting in Moderate to Severe Atopic Dermatitis 
Case Challenge
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2025

Expires: January 30, 2026

Mapping IL-13
Mapping IL-13 to the Clinical Manifestations of Atopic Dermatitis
Case Challenge
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2025

Expires: January 30, 2026

IL-13
Practical Considerations for IL-13
Case Challenge
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2025

Expires: January 30, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the National Eczema Association.

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

National Eczema Association

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner